Curated news and analysis on clinical trials, drug approvals, and medical research.
The FDA has cleared Abbisko Therapeutics' IND application for ABSK061, an oral FGFR2/3 inhibitor for achondroplasia, while BridgeBio reports positive Phase 3 results for its oral infigratinib in the same condition. Both companies are advancing oral therapies targeting FGFR3 overactivity in this genetic growth disorder.
Multiple phase 3 breast cancer trials reported significant findings in early 2026, including positive results for novel therapies across different subtypes. Key data includes progression-free survival benefits for palbociclib in HR-positive, HER2-positive advanced breast cancer and investigations of antibody-drug conjugates and combination therapies. Full trial findings are expected to be presented at upcoming medical meetings.
AI could compress drug development from 10-15 years to as little as six years, accelerating discovery and reducing late-stage trial failures. However, clinical trial execution remains heavily dependent on human oversight, with AI estimated to cut costs only 10-15% while facing regulatory and liability constraints. Major pharma companies like Gilead are investing in AI research centers despite practical limitations in trial implementation.
Recursion reported Q4 2025 financial results with $754 million in cash providing runway into early 2028. The company achieved clinical validation of its AI platform with REC-4881 showing meaningful polyp reductions in FAP patients and received its fifth Sanofi milestone payment. Full-year revenue reached $74.7 million while net loss widened to $644.8 million.
INmune Bio will present new Phase III clinical data for its CORDStrom cell therapy for recessive dystrophic epidermolysis bullosa. The webinar on February 26, 2026, will feature investigators discussing outcomes including skin score improvements and quality-of-life measures. CORDStrom represents a systemic, disease-modifying alternative to topical treatments for this rare skin disorder.
SK pharmteco commits $100 million to expand its viral vector business across U.S. and European sites, while Minaris joins CIRM's Industry Resource Partner Program to provide end-to-end cell and gene therapy manufacturing capabilities to funded innovators. Both moves strengthen manufacturing infrastructure for advanced therapies.
The TrumpRx prescription discount website launched in February 2026 offers coupons for 43 brand-name drugs but has limited usefulness for most patients. Experts found 18 drugs are cheaper through other discount services, and the website doesn't indicate when generic alternatives exist. The program links to broader tariff and pricing policies affecting pharmaceutical companies.
The FDA has granted Priority Review to relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target date of September 2026. Phase 2/3 trial data showed a 53% placebo-adjusted reduction in motor seizures and 66.2% increase in seizure-free days. If approved, it would be the first targeted therapy for these rare, fatal childhood conditions.
The global advanced drug delivery systems market is projected to grow from $255 billion in 2024 to $439.7 billion by 2034 at a 5.6% CAGR. Cardiovascular disease applications dominate with 37.8% market share, while North America leads regionally with 41.3% of the market. Emerging technologies include 3D-printed drug implants, smart hydrogels, and magnetic nanofiber platforms.
Delaware State Police arrested a North Carolina man and seized 2.3 kilograms of cocaine during a traffic stop on I-95. The suspect faces multiple felony drug charges and is being held on $120,801 cash bond. Separate drug investigations in West Virginia and Ohio also resulted in arrests and seizures of fentanyl, methamphetamine, firearms, and child pornography.
The European Medicines Agency has approved Shield Therapeutics' FeRACCRU® for adolescents aged 12 and older, following FDA approval of ACCRUFeR® for children 10+. The expansion was supported by Phase 3 pediatric trial data showing efficacy and safety in children as young as 1 month.
The European Commission has approved KYGEVVI (doxecitine and doxribtimine) as the first treatment for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial disease. Clinical studies showed the drug reduces death risk by 95% and helps 84% of patients regain motor functions. The approval covers pediatric and adult patients with symptom onset before age 12.
Sobi reported 15% revenue growth to SEK 28 billion in 2025 while treating over 53,000 patients. The company published its Annual and Sustainability Report, highlighting pipeline advancements and transition to new sustainability reporting standards.
South Korea has approved fast-track drug listing for rare disease treatments, reducing the insurance coverage process from 240 days to 100 days. The reform includes post-listing effectiveness evaluations and flexible pricing agreements, aiming to improve patient access to innovative treatments amid ongoing budget concerns.
The global GMP consumables market is projected for significant growth through 2035, driven by expansion in biologics, cell and gene therapies, and mRNA vaccine manufacturing. The market will shift from basic contamination control to enabling advanced therapeutic production with specialized single-use systems. Growth will be supported by regulatory standards, supply chain resilience, and increasing biosimilar production in Asia-Pacific and emerging markets.
Pharmaceutical companies are delaying European drug launches due to uncertainty over U.S. pricing policies under President Trump. New drug launches in EU markets fell 35% following Trump's executive order on international reference pricing. Companies fear lower European prices could undermine their ability to maintain higher prices in the $700 billion U.S. market.
A multinational survey shows bridging therapy is used for over 85% of multiple myeloma patients awaiting CAR T-cell therapy, with proteasome inhibitors being the most common approach. Most centers lack standardized protocols and typically bridge patients for 1-2 months, with regimen selection driven primarily by prior therapy history and disease burden.
Researchers have developed a machine learning method called STRUCTURES25 that enables precise quantum chemistry calculations for large drug-like molecules using an orbital-free approach. The breakthrough solves a decades-old stability problem in computational chemistry while reducing computational requirements. This advancement could accelerate drug discovery and materials science research.
The FDA has accepted Praxis Precision Medicines' NDA for relutrigine with priority review and set a PDUFA target date of September 27, 2026. The therapy targets SCN2A and SCN8A developmental and epileptic encephalopathies and could become the first approved treatment for these rare conditions. The company has bolstered its cash position to support commercial launch preparations.
The FDA has granted Priority Review for lirafugratinib, an FGFR2 inhibitor for second-line cholangiocarcinoma treatment, with a PDUFA date of September 27, 2026. Clinical trial data showed a 46.5% objective response rate and 11.8-month median duration of response. The therapy demonstrated a manageable safety profile with lower rates of common FGFR inhibitor side effects.
